HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Brings Dot-Com Disclosure Guide To Social Media, Mobile Era

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised online advertising disclosure guidelines detail FTC’s expectations for how advertisers should craft disclosures in the world of social media and mobile devices.

You may also be interested in...



No Enforcement Immunity For Testimonials On Immunity Or Claims With 'Alert: No COVID-19 Cure'

Elderberry syrup marketer Provezza Health targeted review of claims consumers may link to COVID-19 prevention or treatment due to testimonials not dispelled by the firm. FDA and FTC warn CBD firm to discontinue claims noting immunity-boosting is the “best defense” against COVID-19.

Warning For Facebook “Like” Reflects FDA Social Media Approach

FDA is revealing its views on social media use through individual enforcement actions and provisions in disparate guidances, in the absence of issuing an overarching guidance. A recent warning letter sheds light on the agency’s view of “liking” something on Facebook.

Turning Blogger Relationships Into Gold Takes Careful Management

Mom bloggers have a built-in audience that OTC and supplement marketers want: parents who are looking for the best products for their children and families. But entanglements with bloggers can mean regulatory hot water for firms that don’t carefully manage those relationships.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel